Topics
Adverse Effects and Comorbidities
Antiretroviral Management
Epidemiology and Natural History
Opportunistic Diseases and Coinfection
Pharmacology
Resistance
Special Populations
Viral Tropism
Conference Coverage
2018 Conference on Retroviruses and Opportunistic Infections
2017 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and the European AIDS Conference
9th IAS Conference on HIV Science
2017 Conference on Retroviruses and Opportunistic Infections
IDWeek and HIV Glasgow 2016
More...
Education
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HIV-Infected Patients
Contemporary HIV Management: A Collection of Quick Case-Based Commentaries
Current Controversies in HIV Management
Panel Discussion of Challenging Patient Cases in HIV
CCO Independent Conference Coverage: Clinical Impact of New Data From CROI 2017
More...
ClinicalThought
CROI 2018: Randomized Trial Data on the Risk of IRIS When Starting INSTI-Based ART
How New Data From IAS 2017 May Inform Dual-Therapy Options for HIV Treatment
How New Data From IAS 2017 May Inform Use of ART in Patients With Cardiovascular or Bone Comorbidities
IAS 2017 Data Shed Light on the Potential Use of Investigational ART Coformulations
IAS 2017: How New Data on First-line Dual Therapy and Second-Line ART Are Changing My Practice
More...
Decision Support
inPractice
Decision Support Tools
CCO Live Events
Slidesets & Resources
Audio
Cases
PDF
Slidesets
Video
Save Bookmark
Print
Email to a Colleague
CCO Home
/
HIV
/
Treatment Updates
/ ClinicalThought™
ClinicalThought™
Interact with experts and peers.
Recent Posts
10 of 113 Shown
CROI 2018: Randomized Trial Data on the Risk of IRIS When Starting INSTI-Based ART
Chloe Orkin MBChB, FRCP, MD -
4/17/2018
Should patients with advanced HIV disease be started on INSTI-based regimens?
How New Data From IAS 2017 May Inform Dual-Therapy Options for HIV Treatment
Daniel R. Kuritzkes MD -
9/12/2017
3 comments
/ Last Comment: 10/16/2017
Should dual-therapy ART be considered in the first-line setting for some patients?
How New Data From IAS 2017 May Inform Use of ART in Patients With Cardiovascular or Bone Comorbidities
Daniel R. Kuritzkes MD -
9/11/2017
3 comments
/ Last Comment: 11/12/2017
Can switching ART improve cardiovascular or bone health?
IAS 2017 Data Shed Light on the Potential Use of Investigational ART Coformulations
Daniel R. Kuritzkes MD -
9/11/2017
2 comments
/ Last Comment: 10/16/2017
How do phase III data on bictegravir and doravirine affect the potential future HIV treatment landscape? Here’s my take.
IAS 2017: How New Data on First-line Dual Therapy and Second-Line ART Are Changing My Practice
Babafemi Taiwo MBBS -
8/23/2017
3 comments
/ Last Comment: 9/18/2017
Data presented at the latest IAS meeting highlight how new ART approaches are shifting HIV treatment paradigms. Here is my take.
IAS 2017: A Preview of Key Data to Be Presented in Paris
Anton L. Pozniak MD, FRCP -
7/17/2017
3 comments
/ Last Comment: 7/21/2017
Here is my take on the most anticipated studies that will be presented in Paris this year.
Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data
Eric S. Daar MD -
6/21/2017
2 comments
/ Last Comment: 9/12/2017
For a newly diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
Optimizing ART for a Patient With PI Intolerance and a History of Resistance and Nonadherence
Eric S. Daar MD -
6/21/2017
1 comment
/ Last Comment: 6/22/2017
Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had a history of nonadherence and resistance?
Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR
Eric S. Daar MD -
6/21/2017
1 comment
/ Last Comment: 9/12/2017
What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?
Choosing Statins for Patients With Dyslipidemia and Elevated CVD Risk
David A. Wohl MD -
6/1/2017
2 comments
/ Last Comment: 8/16/2017
Which statins should be avoided in patients receiving boosted ART regimens?
10 of 113 Shown
Show 10 More
Loading...
Filter Content By
Topic:
All topics
Adverse Effects and Comorbidities
Antiretroviral Management
Epidemiology and Natural History
Opportunistic Diseases and Coinfection
Pharmacology
Resistance
Special Populations
Viral Tropism
Subtopic:
All subtopics
Content type:
All content types
Animations
Audio
Capsule Summaries
ClinicalThought Discussions
Decision Tools
Interactive Cases
PDF
Slidesets
Text
Video
Virtual Presentations
Conference only:
Available for credit:
Credit type:
All credit types
AMA
ANCC
ACPE
AAPA
Languages:
All languages
Burmese
Cambodian
Chinese Simplified
Chinese Traditional
English
French
German
Hmong
Italian
Korean
Portuguese
Spanish
Tagalog
Vietnamese
Author:
All authors
Chris Beyrer
Richard E. Chaisson
Francesca Conradie
David A. Cooper
Eric S. Daar
Joseph J. Eron, Jr.
Joel E. Gallant
Giovanni Guaraldi
W. David Hardy
Charles B. Hicks
Lisa Hightow-Weidman
Quarraisha Abdool Karim
Daniel R. Kuritzkes
Josep M. Llibre
Jeanne Marrazzo
Karam Mounzer
Kevin M. O'Hara
Chloe Orkin
William G. Powderly
Anton L. Pozniak
Jürgen K. Rockstroh
Paul E. Sax
Renslow Sherer
Kimberly Y. Smith
Kathleen E. Squires
Donna E. Sweet
Babafemi Taiwo
Mark A. Wainberg
David A. Wohl
Andrew R. Zolopa
Latest Comments
How New Data From IAS 2017 May Inform Use of ART in Patients With Cardiovascular or Bone Comorbidities -
11/12/2017
How New Data From IAS 2017 May Inform Dual-Therapy Options for HIV Treatment -
10/16/2017
IAS 2017 Data Shed Light on the Potential Use of Investigational ART Coformulations -
10/16/2017
Avoiding Drug Interactions Among Hormonal Oral Contraceptives and ARVs -
9/21/2017
IAS 2017: How New Data on First-line Dual Therapy and Second-Line ART Are Changing My Practice -
9/18/2017
Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR -
9/12/2017
Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data -
9/12/2017
Optimal ART During Late Pregnancy After a Break in Therapy -
9/12/2017
ART Switch for Comorbidities in a Middle-Aged Black Woman -
9/11/2017
The Promise of Long-Acting Injectable Antiretroviral Therapies -
9/8/2017